The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BRCA1/2 reversion mutations (BRCArev) in advanced prostate cancer in the absence of prior PARP inhibitor (PARPi) therapy.
 
Douglas I. Lin
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche Pharma AG
 
Elizabeth L
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Natalie Danziger
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Huihui Ye
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics
Honoraria - PATHAI
Consulting or Advisory Role - Janssen Oncology; Radmetrix
Research Funding - Allogene Therapeutics
 
Brennan J. Decker
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche; Vaccitech
Patents, Royalties, Other Intellectual Property - I am an inventor on numerous FMI-owned patent submissions related to research and development activities.
 
Ryon P Graf
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Epic Sciences; Foundation Medicine
 
Jeffrey S. Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Consulting or Advisory Role - Celsius Therapeutics; Tango Therapeutics
Research Funding - Foundation Medicine
 
Julia A. Elvin
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Rana R. McKay
Consulting or Advisory Role - Ambrx; Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)